Innovent Begins Dosing Patients in Phase 3 Trial of Tigulixostat

LG Chem announced on March 23 that Innovent Biologics, which holds the license for its novel gout drug candidate Tigulixostat in China, has begun dosing the first patient in a Phase 3 clinical trial in China.

LG Chem's Out-Licensed Gout Drug Enters Phase 3 Clinical Trial in China View original image

In this Phase 3 trial, Innovent plans to enroll 600 gout patients and conduct a comparative assessment against febuxostat, an existing uric acid-lowering agent. The company will analyze the percentage of patients achieving target serum uric acid levels at week 24, as well as the long-term safety profile over one year of continued use.



Since its establishment in 2011, Innovent has experienced rapid growth through the development and commercialization of novel therapies for cancer and immune diseases. The company is now actively seeking to enter the gout market by adding new drug development programs, including treatments for acute gout flares.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing